- Home
- SILO vs POAI Comparison
SILO vs POAI Comparison
Compare SILO & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SILO
- POAI
- Stock Information
- Founded
- SILO 2010
- POAI 2002
- Country
- SILO United States
- POAI United States
- Employees
- SILO N/A
- POAI N/A
- Industry
- SILO Apparel
- POAI Industrial Specialties
- Sector
- SILO Consumer Discretionary
- POAI Health Care
- Exchange
- SILO Nasdaq
- POAI Nasdaq
- Market Cap
- SILO 8.8M
- POAI 8.5M
- IPO Year
- SILO N/A
- POAI N/A
- Fundamental
- Price
- SILO $1.66
- POAI $1.53
- Analyst Decision
- SILO
- POAI Hold
- Analyst Count
- SILO 0
- POAI 1
- Target Price
- SILO N/A
- POAI N/A
- AVG Volume (30 Days)
- SILO 9.1M
- POAI 2.9M
- Earning Date
- SILO 02-14-2025
- POAI 03-27-2025
- Dividend Yield
- SILO N/A
- POAI N/A
- EPS Growth
- SILO N/A
- POAI N/A
- EPS
- SILO N/A
- POAI N/A
- Revenue
- SILO $72,102.00
- POAI $1,484,223.00
- Revenue This Year
- SILO $1.86
- POAI N/A
- Revenue Next Year
- SILO N/A
- POAI $569.48
- P/E Ratio
- SILO N/A
- POAI N/A
- Revenue Growth
- SILO N/A
- POAI N/A
- 52 Week Low
- SILO $0.77
- POAI $0.55
- 52 Week High
- SILO $4.50
- POAI $3.76
- Technical
- Relative Strength Index (RSI)
- SILO 52.57
- POAI 59.80
- Support Level
- SILO $1.56
- POAI $1.36
- Resistance Level
- SILO $1.89
- POAI $1.58
- Average True Range (ATR)
- SILO 0.19
- POAI 0.21
- MACD
- SILO -0.05
- POAI -0.01
- Stochastic Oscillator
- SILO 27.12
- POAI 30.58
About SILO Silo Pharma Inc.
SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.